磁敏感加权成像无法区分脑转移瘤放疗后放射性坏死与复发:与高级别胶质瘤的比较
该回顾性研究纳入2016年9月至2018年11月56例脑转移瘤和42例高级别胶质瘤患者,计算磁敏感加权成像暗信号占比(proDSI)以鉴别复发与放射性坏死。高级别胶质瘤中复发组proDSI显著低于放射性坏死组(0.13±0.05 vs 0.43±0.11,p<0.001),脑转移瘤中两组无统计学差异(0.49±0.09 vs 0.46±0.08,p=0.26);proDSI对高级别胶质瘤诊断性能最佳(AUC=0.87,95%CI:0.76-0.98;敏感度=0.87;特异度=0.88,阈值0.21)。结论认为SWI半定量分析对高级别胶质瘤可行,对脑转移瘤不可行,临床实践中脑转移瘤放疗后基于SWI的半定量评估应谨慎解读。
要点
- 高级别胶质瘤中复发组proDSI低于放射性坏死组(0.13±0.05 vs 0.43±0.11,p<0.001),可助鉴别。
- 脑转移瘤中复发与放射性坏死组proDSI无统计学差异(0.49±0.09 vs 0.46±0.08,p=0.26)。
- proDSI鉴别高级别胶质瘤复发的AUC=0.87(95%CI:0.76-0.98),阈值0.21时敏感度=0.87、特异度=0.88。
核心结论
- SWI半定量分析可用于高级别胶质瘤复发与放射性坏死的鉴别诊断,但对脑转移瘤不可行。
- 临床实践中脑转移瘤放疗后基于SWI的半定量评估应谨慎解读。
研究设计与样本
- 回顾性研究,纳入2016年9月至2018年11月56例脑转移瘤和42例高级别胶质瘤患者。
- 根据组织病理学或随访结果将脑转移瘤和高级别胶质瘤分为复发组和放射性坏死组。
- 计算每位患者的暗信号强度占比(proDSI),定义为SWI暗信号面积或对比增强T1加权成像(T1WI)强化面积的比例。
- 采用方差分析(ANOVA)及Tukey真实显著差异检验进行重复多重比较,并用受试者工作特征曲线分析验证诊断性能。
关键影像表现/征象
- 高级别胶质瘤中,复发组proDSI显著低于放射性坏死组(0.13±0.05 vs 0.43±0.11,p<0.001)。
- 脑转移瘤中,复发组与放射性坏死组proDSI无统计学差异(0.49±0.09 vs 0.46±0.08,p=0.26)。
诊断标准与关键数值
- proDSI对高级别胶质瘤诊断性能最佳:AUC=0.87(95%CI:0.76-0.98),阈值0.21时敏感度=0.87、特异度=0.88。
临床应用与阅片要点
- 在高级别胶质瘤放疗后,可参考proDSI半定量分析辅助鉴别复发与放射性坏死。
- 在脑转移瘤放疗后,基于SWI的半定量评估应谨慎解读,因proDSI无法区分复发与放射性坏死。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To explore the efficiency of susceptibility-weighted imaging (SWI) in the differential diagnosis of recurrence from radionecrosis in brain metastases (BM) and in high-grade gliomas (HGG).
MATERIALS AND METHODS: From September 2016 to November 2018, 56 patients with BM and 42 patients with HGG were included in this retrospective study. BM and HGG were assigned to the recurrence and radionecrosis groups according to their histopathology or follow-up results. The proportion of dark signal intensity (proDSI), which was defined as the area of dark signal on SWI or the enhancing area on contrast-enhanced T1-weighted imaging (T1WI), was calculated for each patient. Analysis of variance (ANOVA) with Tukey's honestly significant difference test was used for the repeat multiple comparisons. Receiver operating characteristic curve analysis was performed to validate the diagnostic performance.
RESULTS: For HGG, the proDSI in the recurrence group was significantly lower than that in the radionecrosis group (0.13 ± 0.05 versus 0.43 ± 0.11, p<0.001); however, for BM, no statistical difference was found between groups (0.49 ± 0.09 versus 0.46 ± 0.08, p=0.26). proDSI had the best diagnostic performance (AUC = 0.87, 95% CI: 0.76-0.98; sensitivity = 0.87; specificity = 0.88) for HGG, when a cut-off value of 0.21 was selected.
CONCLUSIONS: Semi-quantitative analysis using SWI is feasible for the differential diagnosis between recurrence and radionecrosis in HGG, but is not feasible in BM. Semi-quantitative assessment based on SWI should interpreted with caution in BM after radiotherapy in clinical practice.
引用
- Qin, Yu, Yao, et al. Susceptibility-weighted imaging cannot distinguish radionecrosis from recurrence in brain metastases after radiotherapy: a comparison with high-grade gliomas. Clin Radiol. 2022. PMID: 35676103. doi:10.1016/j.crad.2022.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。